Clinical Trial Update: Study Evaluating HKI-272 in Tumors [Phase 1]

View source ↗

Summary

Phase 1 study evaluating HKI-272 (neratinib) in breast neoplasms has completed with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Neoplasms

Drugs mentioned

• HKI-272 (neratinib)

Snippet

Sponsor: Puma Biotechnology, Inc. | Conditions: Breast Neoplasms | Phase 1 | Status: COMPLETED | Results posted: 2018-02-13